TG Therapeutics, Inc. (TGTX): Price and Financial Metrics
GET POWR RATINGS... FREE!
TGTX POWR Grades
- TGTX scores best on the Value dimension, with a Value rank ahead of 39.3% of US stocks.
- TGTX's strongest trending metric is Momentum; it's been moving down over the last 31 weeks.
- TGTX ranks lowest in Momentum; there it ranks in the 9th percentile.
TGTX Stock Summary
- Tg Therapeutics Inc's capital turnover -- a measure of revenue relative to shareholder's equity -- is better than only 7.78% of US listed stocks.
- TGTX's price/sales ratio is 5,485.6; that's higher than the P/S ratio of 99.66% of US stocks.
- Revenue growth over the past 12 months for Tg Therapeutics Inc comes in at 496.71%, a number that bests 98.51% of the US stocks we're tracking.
- Stocks that are quantitatively similar to TGTX, based on their financial statements, market capitalization, and price volatility, are VHC, CVM, VNRX, CRSP, and AQMS.
- TGTX's SEC filings can be seen here. And to visit Tg Therapeutics Inc's official web site, go to www.tgtherapeutics.com.
TGTX Stock Price Chart Interactive Chart >
TGTX Price/Volume Stats
|Current price||$37.77||52-week high||$56.74|
|Prev. close||$37.97||52-week low||$16.56|
|Day high||$38.12||Avg. volume||1,475,503|
|50-day MA||$39.57||Dividend yield||N/A|
|200-day MA||$38.50||Market Cap||5.34B|
TG Therapeutics, Inc. (TGTX) Company Bio
TG Therapeutics is a biopharmaceutical company focused on the acquisition, development and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. The company was founded in 1993 and is based in New York, New York.
TGTX Latest News Stream
|Loading, please wait...|
TGTX Latest Social Stream
View Full TGTX Social Stream
Latest TGTX News From Around the Web
Below are the latest news stories about Tg Therapeutics Inc that investors may wish to consider to help them evaluate TGTX as an investment opportunity.
TG Therapeutics Announces Data Presentations at the Upcoming 16th International Congress on Malignant Lymphoma
NEW YORK, June 09, 2021 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced the schedule of upcoming data presentations at the 16th International Congress on Malignant Lymphoma (ICML), being held virtually June 18 – 22, 2021. Details of the data presentations are included below. Poster Presentation Title: TG-1701, A Selective Bruton Tyrosine Kinase (BTK) Inhibitor, as Monotherapy and in Combination with Ublituximab and Umbralisib (U2) in Patients with B-cell Malignancies Ab
TG Therapeutics Announces Data from a Phase 1 Study Evaluating TG-1701 as a Monotherapy and as a Triple Combination with Ublituximab and UKONIQ® at the 2021 American Society of Clinical Oncology Annual Meeting
100% ORR in CLL patients treated with 300 mg QD of TG-1701 monotherapy (n=19) Triple combination of ublituximab and UKONIQ (U2) + TG-1701 cohort (n=19) resulted in 79% ORR, with 21% CR rate, including 100% ORR in patients WM, CLL, MZL, MCL, and DLBCL (n=11) NEW YORK, June 04, 2021 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced data from TG-1701, the Company’s investigational once-daily, oral BTK inhibitor, as a monotherapy and as a triple therapy in combination with ub
TG Therapeutics' Ublituximab-Umbralisib Combo Application Under FDA Review for Hematological Malignancies
The FDA has accepted for review TG Therapeutics Inc's (NASDAQ: TGTX ) marketing application seeking approval for ublituximab in combination with Ukoniq (umbralisib) for chronic lymphocytic leukemia … Full story available on Benzinga.com
TG Therapeutics Announces FDA Acceptance of Biologics License Application for Ublituximab in Combination with UKONIQ® (umbralisib) as a Treatment for Patients with Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma
Prescription Drug User Fee Act (PDUFA) goal date of March 25, 2022NEW YORK, May 25, 2021 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced that the U.S. Food and Drug Administration (FDA) has accepted the Biologics License Application (BLA) for ublituximab, the Company’s investigational glycoengineered anti-CD20 monoclonal antibody, in combination with UKONIQ® (umbralisib), the Company’s once-daily, oral, inhibitor of PI3K-delta and CK1-epsilon, as a treatment for patients with chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL). The FDA has set a Prescription Drug User Fee Act (PDUFA) goal date of March 25, 2022. The FDA also notified the Company that it is not currently planning to hold an advisory committee meeting to discuss this applicati...
NEW YORK, May 13, 2021 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced the schedule of upcoming data presentations at the American Society of Clinical Oncology (ASCO) annual meeting, to be held virtually June 4 – 8, 2021 and the European Hematology Association (EHA) annual congress, to be held virtually June 9 – 17, 2021. Details of the data presentations are included below. Michael S. Weiss, the Company’s Executive Chairman and Chief Executive Officer stated, “We are excited to share updated data for TG-1701, our novel BTK inhibitor, as a monotherapy, and as a triple therapy with U2, at the upcoming ASCO and EHA annual congresses. The EHA abstract released yesterday included an update from the data most recently presented at the ASH 2020 congress, and we are p...
TGTX Price Returns